SEC ENFORCEMENT | 2026-04-04

SEC Biotech Insider Trading Crackdown 2026 | Securities Attorney California

SEC and DOJ intensify coordinated insider trading enforcement in the biotech and pharmaceutical sector with significant implications for California's biotech hub companies and executives

By Anatolii Trembach, Esq. (California State Bar No. 349304; LL.M., USC Gould School of Law; admitted to the U.S. Court of International Trade), Trembach Law Firm, APC · Published

The Securities and Exchange Commission and the Department of Justice have intensified coordinated enforcement against insider trading in the biotechnology and pharmaceutical sectors in 2026, with multiple enforcement actions targeting individuals who traded on material nonpublic information related to clinical trial data and FDA regulatory decisions. On January 15, 2026, the SEC charged Hong Wang and Precision Clinical Consulting LLC with insider trading in C4 Therapeutics stock, alleging that W

Contact Trembach Law Firm at (818) 514-7680 for a confidential consultation.

Trembach Law Firm | 27001 Agoura Road, Suite 350, Calabasas, CA 91301